Lithium carbonate

Alzamend Neuro to present non-clinical data on AL001, a lithium-based treatment, at the Society of Toxicology 2025 Annual Meeting, showing enhanced brain-specific lithium delivery with minimized systemic exposure and no adverse effects. The company plans five Phase II trials in 2025 targeting Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD, aiming for FDA 505(b)(2) approval.

Alzamend Neuro partners with Massachusetts General Hospital for a Phase II clinical trial of AL001, a next-generation lithium therapeutic for bipolar disorder, with Dr. Ovidiu Andronesi as principal investigator. The study aims to compare AL001's safety and effectiveness to current lithium products by analyzing lithium levels in the brain.

Lithium, an element from the Big Bang, is now a popular ingredient in wellness products like bath soaks and supplements, despite limited research on its effectiveness. Historically, lithium has been used to treat various ailments and was even an ingredient in 7 Up. While high doses are used for mood disorders, low-dose lithium's benefits remain uncertain, with mixed results from studies on its effects on suicide rates, dementia, and longevity. The lack of patentability and FDA regulation for dietary supplements means companies have little incentive to conduct rigorous research, leaving consumers in a gray area regarding its safety and efficacy.

CTL investigates iFO for eluate concentration, achieving higher water recovery and up to 60% lower energy consumption and CO2 emissions compared to conventional thermal evaporators. An iFO demonstration unit from Forward Water Technology is set to be shipped to Conductive Energy in Chicago for converting eluate from Laguna Verde into battery-grade lithium carbonate. CTL is assessing both iFO and thermal evaporators for the Laguna Verde PFS, with initial results showing potential benefits in energy and cost reduction.